For its third fiscal quarter (ending September 30), NovoCure Ltd (NASDAQ: NVCR) has reported a -39% decline in E.P.S. from $-0.46 a year ago to $-0.28 in the current quarter. E.P.S. were $-1.40 for the latest four quarters through September 30 versus $-1.87 for the same period a year ago — a decline of -25%.
Recent Price Action
On 10/30/24, NovoCure Ltd (NASDAQ: NVCR) stock rose modestly by 0.6%, closing at $16.99. Moreover, this advance was accompanied by unusually high trading volume at 152% of normal. The stock has risen 5.2% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, NVCR is expected to continue to be Value Creation neutral.
NovoCure has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. NovoCure has a very low Appreciation Score of 10 but a neutral Power Rating of 60, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment